Although magrolimab has been approved for the treatment of hematopoietic malignancies and several other CD47/SIRPα inhibitors have been assessed in many advanced cancers [307–310], clinical data about the efficacy of CD47/SIRPα inhibitors in patients with gynecological cancers are rare. Here, CD47 is linked to female reproductive organ cancer.